Biora Therapeutics, Inc (BIOR) - Gross Profit Rate

Official company branding of Progenity (BIOR)

Biora Therapeutics (BIOR) maintains an effective gross margin that demonstrates operational resilience, with the 50.30 metric confirming current levels. Biora Therapeutics is recognized as an innovator in targeted gastrointestinal drug delivery, replacing injections with capsules. The development of the NaviCap platform relies on partnerships with pharma behemoths to accelerate releases. Stability is ensured by a strong team of bioengineers attracted by the success of early clinical trials.

bioratherapeutics.com (BIOR) - Gross Margin from 04/28/2023 to 12/14/2024

Analytical breakdowns and data insights for company Biora Therapeutics (BIOR)

- market value and analyst target forecast:
Fundamental valuation:Biora Therapeutics
Signature product of Biora Therapeutics, Inc

The Biora Therapeutics (BIOR) model relies on the creation of innovative smart capsules for the non-invasive delivery of biologics to the gastrointestinal tract. By analyzing the gross profit margin within the revenue, an investor can see the portion of funds remaining after deducting direct production costs. This metric determines the efficiency of the cost base and the company's ability to scale the technology, which serves as a key criterion when assessing the long-term investment attractiveness of the startup.